Dr. Kirk Shepard, CMO, SVP, & Head of Global Medical Affairs, Oncology Business Group at Eisai Inc, discusses the final study results from the KEYNOTE-146/Study 111 presented at the 2019 European Society for Medical Oncology (ESMO) Congress, evaluating KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) combination for the treatment of advanced endometrial cancer. Merck and Eisai known as MSD outside the United States and Canada, are in collaboration for the worldwide co-development and co-commercialization of LENVIMA.

#KEYTRUDA #ESMO #EndometrialCancer



Visit our website
www.healtprofessionalradio.com.au

Follow us on our social media channels
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
Google+: [ Ссылка ]...
Pinterest: [ Ссылка ]...
Linkedin: [ Ссылка ]...
Instagram: [ Ссылка ]...

Subscribe to our podcast channels
Soundcloud: [ Ссылка ]...
Itunes: [ Ссылка ]...

Support us on Patreon
[ Ссылка ]

keytruda immunotherapy
keytruda success stories
keytruda
keytruda commercial 2019
keytruda side effects
keytruda lung cancer success stories
keytruda lung cancer
keytruda melanoma
keytruda mechanism of action
keytruda pronounce
keytruda price
keytruda philippines cost
keytruda philippines
keytruda indications
keytruda manufacturer
keytruda cost
keytruda contraindications
keytruda philippines price
keytruda immunotherapy drug
keytruda immunotherapy for breast cancer
keytruda immunotherapy for ovarian cancer
keytruda immunotherapy cost
keytruda immunotherapy side effects
keytruda immunotherapy treatment
keytruda immunotherapy for lung cancer
keytruda immunotherapy for melanoma
keytruda immunotherapy for pancreatic cancer
keytruda success stories lung cancer
keytruda success stories bladder cancer
keytruda success stories ovarian cancer
keytruda success stories melanoma
keytruda colon cancer success stories
keytruda success
keytruda tv commercial

свернуть